N4 Pharma PLC Work Programme Update (5530O)
13 Giugno 2022 - 8:00AM
UK Regulatory
TIDMN4P
RNS Number : 5530O
N4 Pharma PLC
13 June 2022
13 June 2022
N4 Pharma Plc
("N4 Pharma" or the "Company")
Work Programme Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to announce an update on its current work
programmes.
Highlights:
-- Medicines Discovery Catapult study shows demonstrable
suppression of tumour growth using a reduced load of TNFalpha with
Nuvec(R), enhancing data set from previous successful studies.
Further results on the mechanism of action to follow
-- Successful loading of Nuvec(R) with SiRNA and transfection in
vitro showing clear gene suppression
-- Positive preliminary results from ongoing oral studies
undertaken at the University of Queensland ('UQ') showing Nuvec(R)
delivered orally has transfected cells in the small intestine
-- Material Transfer Agreement ("MTA") remains ongoing
Oncology work
Following the successful oncology studies concluded last year,
the Company has been undertaking an expanded study to better
understand the mechanism that produced the tumour suppression. The
Company is pleased that the study showed clear tumour suppression
with 10ug of the TNFalpha loaded onto Nuvec(R) which was a lower
dose than used in the earlier studies. In this study, the dose
preparation at a higher dose was sub-optimal and data from this
dose could not be obtained. Further work to optimise formulations
for in vivo studies continues .
Biochemical analysis of blood and tissue samples is continuing
to determine whether the Nuvec(R) loaded with TNFalpha was directly
taken up by the tumour cells to produce the active TNF within the
tumour or whether other organs such as the liver took up the
Nuvec(R) and produced the TNF and released it systemically to
suppress the tumour. If it can be demonstrated that Nuvec(R) can
selectively deliver the plasmid to the tumour this may indicate the
potential use of Nuvec(R) to deliver to tumours with a reduced
systemic effect and inform the scope of any clinical studies. This
analysis remains ongoing and the results are expected in the next
four to six weeks.
The posters resulting from the previous oncology studies
undertaken by Nanomerics are due to be presented at the CRS Annual
Meeting to be held in Montreal, Canada, between the 11 and 15 July
at which point they will be published on the Company's website.
SiRNA
In addition to evaluating the potential of Nuvec (R) to carry
DNA and mRNA, experiments have shown that Nuvec (R) can also be
loaded with SiRNA and maintain a colloidally stable formulation.
Experimental work is ongoing to establish the number of SiRNA
strands that can be loaded on Nuvec (R) and to determine the
minimal functional load. The application of specific SiRNAs in
oncology is a rapidly developing field and this may represent a
further extension of the use of Nuvec (R) .
Oral Applications for Nuvec(R)
As announced previously, a longer term study on oral
applications is being carried out at UQ utilising grant funding
obtained by N4 Pharma and UQ for this purpose. Early results are
promising with UQ having successfully demonstrated via an in vivo
pre-clinical study that Nuvec(R) loaded with McCherry DNA ( a
commonly used form of labelled DNA to track expression) and
formulated and administered in capsules was able to pass through
the lining of the stomach to successfully transfect the small
intestine. Whilst there is a lot more work to do in this area this
is a significant step in establishing how Nuvec(R) could be
delivered orally.
Nigel Theobald, Chief Executive Officer of the Company,
commented : "We are very pleased with our recent results across
oncology, the potential opening up of the siRNA market and the
early data coming from UQ on their oral work.
"We have now demonstrated across 50ug, 20ug and now 10ug of TNF
alpha loaded onto Nuvec(R) results in tumour suppression in vivo.
We now wait with interest the further data due on this study to
better understand how the suppression has occurred which will help
determine the most appropriate use of Nuvec(R) as a delivery system
to help treat tumours.
"Our proof of concept work is extremely encouraging and, again,
points towards multiple applications that Nuvec(R) could be used
for, although it is clear that precise formulation for use in each
area will be critical when advancing towards a commercial product .
Our work with our MTA partner continues and I look forward to
providing an update on the next steps following the final results
of the oncology work."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 which has been
incorporated into UK law by the European Union (Withdrawal) Act
2018.
Enquiries:
N4 Pharma Plc Via IFC Advisory
Nigel Theobald, CEO
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: + 44 (0)20 3470
Nominated Adviser and Joint Broker 0470
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
IFC Advisory Limited Tel: +44 (0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFFLLRAILLIF
(END) Dow Jones Newswires
June 13, 2022 02:00 ET (06:00 GMT)
Grafico Azioni N4 Pharma (LSE:N4P)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni N4 Pharma (LSE:N4P)
Storico
Da Apr 2023 a Apr 2024